skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

The UK Medicines and Healthcare products Regulatory Agency has appointed former life sciences industry executive Stephen Lightfoot as its new chair.

Lightfoot, who has been a non-executive director of the MHRA since September 2015, will take up the new position on 1 September. He succeeds Sir Michael Rawlins, who has been the chair of the agency board since December 2014.

Lightfoot will take on his new role at a pivotal time in the agency’s history as it undergoes organizational transformation. Steering the MHRA through Brexit-related challenges will be a key task for the new chair, particularly after the transition period ends on 31 December. He also takes up the post as the MHRA continues to deal with the COVID-19 pandemic.

Industry Experience

Lightfoot, who is also deputy chair of Sussex Community NHS Foundation Trust and non-executive chair of Sussex Primary Care Limited, has had a 30-year career in the life sciences industry. 

He has worked on the development and commercialization of a wide range of medicines and medical devices in UK and global health care companies, the MHRA said in a 24 August statement announcing his appointment. His most recent executive roles were general manager of the global pharmaceutical diagnostics business of GE Healthcare, managing director of the UK pharmaceutical business of Daiichi Sankyo, and commercial director of the UK pharmaceutical and medical device business of Schering Healthcare.

Lightfoot will become the fourth person to chair the MHRA board, following Sir Alasdair Breckenridge, Sir Gordon Duff and Sir Michael.

“The Agency has a world class reputation and my ambition is for us to become an ‘enabler’ in the UK health system by developing new regulatory processes which are proportionate, evidence-based and transparent, so that patients can gain earlier and safer access to new medical products than ever before” he said.

Hunt Still On For A Chief Executive

Meanwhile, the MHRA is still looking for a permanent chief executive to lead the agency, after Ian Hudson stepped down from the post in September 2019 and June Raine stepped in as the interim chief executive.

Hudson had originally announced his plan to step down in November 2018, and the agency had been expected to start recruiting for his successor in early 2019. 

The MHRA told the Pink Sheet today: “There will be a recruitment campaign to make a permanent appointment in due course, led by the Department of Health and Social Care.” Raine, meanwhile, is continuing as the interim postholder. 

The agency has previously said it was not unusual for recruitment to a senior role to take some time.

おすすめのニュース&レポート

;

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問合せの際は下記メールアドレスまたは各営業スタッフまでご連絡下さいますようご協力をお願い申し上げます。

インフォーマインテリジェンス合同会社
ファーマインテリジェンス
inquiry.jp@informa.com

*Omdia(ICT産業の情報)に関するお問い合わせはこちら
Contact_OmdiaJapan@omdia.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。